Isildar, B. Et Al. 2024. Preconditioning of human umbilical cord mesenchymal stem cells with deferoxamine potentiates the capacity of the secretome released from the cells and promotes immunomodulation and beta cell regeneration in a rat model of type 1 diabetes. International Immunopharmacology , vol.129 .

Isildar, B., Ozkan, S., ŞAHİN, H., ERÇİN, M., Gezginci-Oktayoglu, S., & KOYUTÜRK, M., (2024). Preconditioning of human umbilical cord mesenchymal stem cells with deferoxamine potentiates the capacity of the secretome released from the cells and promotes immunomodulation and beta cell regeneration in a rat model of type 1 diabetes. International Immunopharmacology , vol.129.

Isildar, Başak Et Al. "Preconditioning of human umbilical cord mesenchymal stem cells with deferoxamine potentiates the capacity of the secretome released from the cells and promotes immunomodulation and beta cell regeneration in a rat model of type 1 diabetes," International Immunopharmacology , vol.129, 2024

Isildar, Başak Et Al. "Preconditioning of human umbilical cord mesenchymal stem cells with deferoxamine potentiates the capacity of the secretome released from the cells and promotes immunomodulation and beta cell regeneration in a rat model of type 1 diabetes." International Immunopharmacology , vol.129, 2024

Isildar, B. Et Al. (2024) . "Preconditioning of human umbilical cord mesenchymal stem cells with deferoxamine potentiates the capacity of the secretome released from the cells and promotes immunomodulation and beta cell regeneration in a rat model of type 1 diabetes." International Immunopharmacology , vol.129.

@article{article, author={Başak IŞILDAR Et Al. }, title={Preconditioning of human umbilical cord mesenchymal stem cells with deferoxamine potentiates the capacity of the secretome released from the cells and promotes immunomodulation and beta cell regeneration in a rat model of type 1 diabetes}, journal={International Immunopharmacology}, year=2024}